Pemphigus vulgaris is one of the most feared diseases in dermatology, a rare autoimmune condition in which the body’s own antibodies turn against the glue that holds skin cells together. Patients develop painful, blistering erosions of the skin and mucous membranes that can spread across large areas of the body, and before the era of corticosteroids the disease was frequently fatal. While treatments have dramatically improved survival, the disease relapses often, and doctors still cannot predict who will develop it or how severely. Now, a new study published in the journal Immunogenetics has taken one of the most detailed looks yet at the genetic machinery behind the disease, combining classical immunogenetics with modern machine learning to map how two key immune genes jointly shape a person’s risk. The work, led by Burak Kaan Kasap and colleagues at Karadeniz Technical University in Turkey, offers a fresh and somewhat sobering picture: one genetic component towers over everything else, while a second, long-suspected player appears to act only as a quiet modulator at best.
The biological story of pemphigus vulgaris begins with a molecular error of recognition. The disease is driven by immunoglobulin G autoantibodies that target desmoglein-3 and desmoglein-1, two cadherin-type adhesion molecules that maintain the cohesion of keratinocytes, the dominant cells of the epidermis. When these antibodies bind their targets, the desmosomal junctions that tether skin cells to one another fall apart, a process called acantholysis, and blisters form within the epithelium. Why the immune system produces these antibodies in the first place has long been the central question. Decades of evidence have pointed to genetics as a major determinant, and among all the candidate regions of the genome, one stands out above the rest: the human leukocyte antigen complex, and specifically the HLA-DRB1 gene, which encodes a class II molecule responsible for presenting fragments of proteins to CD4-positive T cells.
Previous studies across Ashkenazi Jewish, Mediterranean, and South Asian populations had already flagged several HLA-DRB1 alleles, including 04:02, 14:01, and 08:04, as risk factors, while alleles such as 07:01 appeared protective in some ethnic groups. The prevailing explanation is that certain HLA-DRB1 variants present self-antigens such as desmogleins to autoreactive T cells with particular efficiency, breaking immune tolerance and setting the antibody production cascade in motion. But HLA variation alone has never fully explained why some carriers develop the disease and others never do, nor why clinical severity varies so widely between patients. That gap pushed researchers toward non-HLA genes that regulate immune signaling, and one candidate in particular has attracted growing interest: FCGR2B, the gene encoding Fc gamma receptor IIB.
FCGR2B occupies a special place in immune physiology because it is the only inhibitory Fc receptor expressed on B cells and macrophages. In effect, it acts as a brake on antibody production, dampening B-cell activation whenever antibodies are abundant. A well-known functional polymorphism in the gene, the I232T variant, substitutes a threonine for isoleucine at position 232 in the transmembrane domain, and this single amino acid change impairs the receptor’s ability to inhibit B-cell signaling. The variant has been linked to heightened B-cell responsiveness and to autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, making it an obvious suspect in pemphigus vulgaris, which is itself an antibody-driven disorder. What has been missing is evidence: almost no previous study had systematically examined HLA-DRB1 and FCGR2B together in the same group of patients.
The Turkish team designed their study to fill exactly that gap. They enrolled 286 participants, 86 patients with confirmed pemphigus vulgaris and 200 healthy controls, all recruited from the dermatology clinics of the Karadeniz Technical University Faculty of Medicine. Every patient diagnosis was anchored in hard evidence: characteristic clinical presentation, histopathological confirmation of intraepithelial acantholysis, and positive direct immunofluorescence or enzyme-linked immunosorbent assay results for desmoglein antibodies. Controls had no history of autoimmune or skin disease and came from the same geographic catchment area. The two groups were well matched, showing no statistically significant differences in age or sex distribution, and the study was conducted under institutional ethics approval in accordance with the Declaration of Helsinki.
On the laboratory side, the researchers deployed a demanding two-pronged genotyping strategy. HLA-DRB1 typing was performed with the PCR sequence-specific oligonucleotide probe method using fluorescent microbead technology, the Luminex platform that allows high-resolution allele assignment. FCGR2B presented a trickier problem because exon 5, which contains the I232T variant, is highly homologous to the paralogous gene FCGR2C, and indiscriminate amplification could yield misleading genotype calls. The team therefore designed a two-step PCR protocol with long-range amplification followed by nested PCR, validated in silico to guarantee locus specificity, and then sequenced the purified amplicons by the Sanger method. Genotype completeness reached 100 percent with no missing data, and control-group genotype frequencies were consistent with Hardy–Weinberg equilibrium, an important quality benchmark that the results below rest on solid footing.
The statistical findings were striking. After correcting for multiple testing using the Benjamini–Hochberg false discovery rate procedure, two alleles emerged as significant risk factors: HLA-DRB104:02, with an odds ratio of roughly 30, and HLA-DRB114:01. Two other alleles, 11:01 and 16:01, showed significant protective effects. The magnitude of the *04:02 association is remarkable even by the standards of autoimmune genetics, suggesting that this allele is a dominant gateway to disease susceptibility in this population. The FCGR2B I232T variant, by contrast, showed only a modest effect in single-locus analyses, and that effect did not survive correction for multiple testing. Several two-locus genotype combinations involving the two genes were enriched among patients, hinting at some joint contribution, but formal interaction testing told a different story: the data supported an additive immunogenetic architecture rather than epistasis, meaning the genes contribute independently rather than amplifying one another.
To push the analysis beyond classical statistics, the researchers turned to explainable machine learning. They built a predictive model using XGBoost, a gradient-boosted decision tree algorithm, and interpreted it with SHAP values, a technique that quantifies how much each feature contributes to each individual prediction. The results reinforced the hierarchy seen in the regression analyses: HLA-DRB1 was identified as the dominant predictor of disease status, while FCGR2B contributed a secondary modulatory signal. Weighted genetic risk scores that incorporated both loci improved the discrimination between patients and controls compared with single-locus models, offering a glimpse of how genetics-based risk assessment for autoimmune blistering disease might eventually look in practice.
The study also added a functional layer. Using biological annotation and network mapping tools, including Gene Ontology, KEGG pathway analysis, and the STRING protein–protein interaction database, the authors explored the molecular neighborhoods in which the two gene products operate. This integrative view connects the antigen-presenting function of HLA-DRB1, which initiates the loss of tolerance, with the inhibitory signaling role of FCGR2B, which in principle governs how vigorously B cells respond once autoreactivity has been triggered. The picture that emerges is coherent: a strong initiating signal from HLA drives the autoimmune process, while the inhibitory receptor variant may fine-tune the intensity of the antibody response without being, by itself, sufficient to cause disease.
The researchers are candid about the limits of their work. With 86 patients, the study has moderate statistical power, and effects that are real but small, such as a genuine contribution from FCGR2B, may simply have been missed. All participants came from a single geographic region, so the findings may not generalize to other populations where different HLA alleles predominate. And the study design, while rigorous, remains observational; association, even at an odds ratio of 30, is not proof of mechanism. Larger, multi-center cohorts and functional studies in cellular models will be needed to confirm whether the I232T variant truly modulates disease expression and to determine how HLA-DRB1 alleles shape the presentation of desmoglein peptides to T cells.
Even so, the study represents a meaningful step forward in how pemphigus vulgaris is conceptualized. Rather than treating HLA and non-HLA genes as separate research silos, the work demonstrates the value of analyzing them together within a single statistical and computational framework, one that combines penalized regression, gene–gene interaction modeling, functional annotation, and interpretable artificial intelligence. For patients, the promise lies in precision: if the genetic architecture of susceptibility can be quantified with weighted risk scores, clinicians may one day identify individuals at elevated risk before blisters ever appear, opening a window for monitoring and early intervention. For now, the message is clear and humbling: in the immunogenetics of pemphigus vulgaris, HLA-DRB1 reigns supreme, and everything else modulates from the margins.
Subject of Research: Genetic and immunological determinants of susceptibility to pemphigus vulgaris, focusing on the combined roles of HLA-DRB1 alleles and the FCGR2B I232T variant in an additive immunogenetic architecture.
Subject of Research: Biology
Article Title: Genetic and immunological determinants of Pemphigus vulgaris: integrative analysis of HLA-DRB1 and FCGR2B variants
Article References: Kasap, B. K., Toraman, B., Kurt, B., Ermis, H., & Arıca, D. A. (2026). Genetic and immunological determinants of Pemphigus vulgaris: integrative analysis of HLA-DRB1 and FCGR2B variants. Immunogenetics, 78(1), Article 9. https://doi.org/10.1007/s00251-026-01402-5
Image Credits: AI Generated
DOI: 10.1007/s00251-026-01402-5
Keywords: pemphigus vulgaris, HLA-DRB1, FCGR2B, immunogenetics, autoimmune blistering disease, desmoglein, autoantibodies, genetic risk score, XGBoost, SHAP, epistasis, Fc gamma receptor IIB
Cite Scienmag News
APA MLA Chicago
Juliet Wilcox. (September 11, 2026). HLA-DRB1 and FCGR2B variants shape immune risk in Pemphigus vulgaris. Scienmag. https://scienmag.com/hla-drb1-and-fcgr2b-variants-shape-immune-risk-in-pemphigus-vulgaris/
Juliet Wilcox. “HLA-DRB1 and FCGR2B variants shape immune risk in Pemphigus vulgaris.” Scienmag, 11 September 2026, https://scienmag.com/hla-drb1-and-fcgr2b-variants-shape-immune-risk-in-pemphigus-vulgaris/. Accessed 11 September 2026.
Juliet Wilcox. “HLA-DRB1 and FCGR2B variants shape immune risk in Pemphigus vulgaris.” Scienmag. September 11, 2026. https://scienmag.com/hla-drb1-and-fcgr2b-variants-shape-immune-risk-in-pemphigus-vulgaris/
Copy citation Download RIS
Tags: autoantibody-mediated skin diseaseautoimmune skin blistering diseasedesmoglein autoantibodies in pemphigus vulgarisdesmoglein autoimmunity in pemphigus vulgarisFCGR2B variants andgenetic prediction of autoimmune disease severitygenetic predisposition to autoimmune blistering diseasesgenetic predisposition to autoimmune skin conditionsHLA-DRB1 and FCGR2B gene variantsimmune gene modulation of disease severityimmune system modulation in blistering diseasesimmunogenetics and machine learning in autoimmune researchimmunogenetics and machine learning in disease predictionimpact of HLA-impact of HLA-DRB1 on immune responsePemphigus vulgaris genetic risk factorsrole of autoantibodies in pemphigus vulgarisrole of immune genes in pemphigus vulgaris
